By Ruth Massey and Adam Roberts, The Conversation
Hard-to-kill bacteria or “superbugs” have become a major problem for hospitals. Between 5% and 12% of hospital patients in the EU are thought to acquire an infection during their stay, with many caused by bacteria such as Clostridium difficile (C. diff) that are resistant to antibiotics.
In the US, C. diff is the leading cause of hospital-acquired infections and, in the UK – although it is declining – it remains a major healthcare problem implicated in thousands of deaths every year. But a group of researchers believe they may have found a surprising answer to treating C. diff: giving patients another dose of the bacterium.
The effects of C. diff range from mild diarrhoea to more serious and life-threatening conditions such as pseudomembraneous colitis (inflammation of the intestines) and toxic megacolon, which often require surgery to remove the affected tissue and can be fatal.
Despite being a major human pathogen, C. diff is actually part of the normal group of microorganisms found in the gut (in 3% of healthy adults). But sometimes it takes advantage of disruptions in our bacterial flora to cause disease. These changes are typically caused when antibiotics are used to treat an unrelated condition, killing off the protective microorganisms of our gut and allowing C. diff to flourish.
Paradoxically, more antibiotics are typically used in an attempt to kill off the C. diff as well. However, this can create the same problem again, leading to a recurrence of the infection in approximately 30% of cases. And once the infection has recurred once, it recurs again in 60% of cases. This has led doctors to consider many alternative strategies.
Giving patients bacteria thought to promote a healthy digestive system (probiotics) has been tried as a way of replacing the normal gut flora killed by antibiotics, but with little evidence of success.
More recently, trials have begun with the more controversial “faecal transplants”. Both selected bacteria from the faeces of a healthy donor and entire samples faecal matter have been implanted in a patient’s colon to test the idea. There is a growing body of evidence to suggest this can provide both resolution and protection from recurrence.
Researchers from Loyola University Health System in Illinois have now published a trial of a technique that could be described as a more refined and specific version of probiotic treatment or faecal transplant. Rather than replacing the entire gut-flora of an individual, the researchers introduced a different, harmless strain of C. diff that doesn’t produce any toxins.
Having already conducted an initial trial, the researchers expected that the non-toxic bacteria would outcompete the toxic strain and prevent the progression and recurrence of infection. The latest trial demonstrated the safety of the treatment and presented further evidence for its efficacy. The most effective dose of bacteria reduced the rate of recurrence to 5%, compared to 30% in a placebo group.
This is an extremely encouraging result. The next stage in the translation of this into the clinic is a phase III trial which will determine the efficacy and safety over many thousands of diverse patients. If successful this could lead to an incredible, cost-effective and widely applicable treatment. Further work is needed to understand why and how this non-toxic strain outcompetes the toxic strains in the gut.
There is a cautionary note, however. C. diff has been shown to transfer its DNA (containing the toxin genes) from toxic strains to non-toxic strains in the laboratory. If the non-toxin strain is inherently more fit in the human gut than the toxic ones, and if it could readily acquire the toxin genes and become a fitter toxic strain, we may head straight back to square one. This would add yet another, even more dangerous superbug to the ever-growing list.
Ruth Massey is a senior lecturer in the department of biology & biochemistry at University of Bath. Adam Roberts is a senior lecturer at UCL. This article first appeared on The Conversation and is republished here under Creative Commons license. Image by Sanofi Pasteur under Creative Commons license.